After announcing it had raised another $100 million — nearly doubling its capital base — startup Truveta launched its data platform for research and drug development and shared highlights from its COVID-19 breakthrough infection research.
The company, created in 2020, partners with about 20 health systems that provide roughly 16% of all care delivered in the U.S. Truveta has begun to de-identify and aggregate data from its member organizations to provide medical insights.
Among the insights gleaned from its early analysis into COVID-19 breakthrough infections, the company shared the following:
- Between 9% and 15% of fully vaccinated people who have a breakthrough infection end up hospitalized, with Johnson & Johnson’s vaccine having the highest hospitalization rate.
- Less than 1% of vaccinated people experience adverse events, with Moderna recipients having the most adverse events.
- Patients with certain chronic conditions like diabetes, chronic lung or kidney disease were nearly twice as likely to be hospitalized, consistent with findings from other studies.
Data from the Truveta platform is available to researchers within the company’s partner institutions, including Providence, Advocate Aurora Health, Northwell Health and Tenet. Ochsner Health, Saint Luke’s Health System and UnityPoint Health are the latest organizations to join Truveta.